STEERING PROGRESS,
SHAPING THE FUTURE
Medigrowth is committed to advancing cannabinoid science through our bench-to-patient research program. Our ability to utilise expertise and consolidate university-led research, plant genetics and selective breeding programs, proprietary cultivation techniques and drug development pathways will offer long-term industry engagement and academic contribution and progression. Industry partnerships and university-led initiatives allow Medigrowth to be an active player in industry development and discovery.
MEDIGROWTH AND DEAKIN UNIVERSITY:
Innovation, collaboration AND world class research
The Deakin-Medigrowth relationship is anchored in collaboration and commitment to world class research with real world outcomes via plant science, translational research initiatives and implementation of joint PhD programs and postgraduate training. We share an exciting future together as we collectively develop and explore the scientific and therapeutic potential of cannabinoids and full-spectrum cannabis extracts.
-
EFFECTS OF CANNABIDIOL IN CHILDREN WITH AUTISM (CBDCA)
Approved by Deakin University Human Research Ethics Committee (DUHREC 071_2022).
Status: Completed
Publications:
Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomised Controlled Crossover Trial (published December 2025).
Cannabidiol Modulates Right Fronto-Parietal Connectivity in Autistic Children: A Secondary EEG Analysis from a Randomised Placebo-Controlled Crossover Trial (preprint; under peer review for publication).
-
01
MEDIGROWTH LONGITUDINAL OBSERVATIONAL STUDY
Approved by Deakin University Human Ethics Advisory Group (DUHEAG 166_2022).
Status: Recruitment closed.
02
THE EMPOWER PROJECT
Approved by Deakin University Human Research Ethics Committee (2025/HE000503).
Status: Not yet recruiting.
